Bringing the fundamentals into focus…
Back to Neurocrine Biosciences, Inc.
How Neurocrine Biosciences, Inc. stacks up
NBIX · against 127 other Healthcare companies of similar size
Valuation
64/ 100
Above the middle of the pack.
Ranked #49 of 128 · scores higher than 61% of peers
Bars: peers in each 10-point band of the valuation score25 peers with a valuation score of 60–69, including NBIX · Click a bar to see the companies
Why valuation scores 64?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its free cash flow yield and earnings yield, which are stronger than most Healthcare peers.
- EBITDA yield is close to the peer norm. EBITDA yield: 5.4% vs peer median 4.0%
- higher earnings for the price paid: stronger than 72% of peers. Earnings yield: 4.2% vs peer median 1.5%
- more free cash flow for the price paid: stronger than 80% of peers. Free cash flow yield: 5.2% vs peer median 0.0%
Metric by metric
Position: dot = NBIX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | NBIX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 126 reported | 4.1% | 2.9% | 72% | 30% | |
| EBITDA yieldHigher is better · 129 reported | 5.4% | 5.2% | 53% | 50% | |
| Free cash flow yieldHigher is better · 84 reported | 5.2% | 3.1% | 76% | 20% | |
| Book yieldHigher is better · 125 reported | 22.1% | 21.0% | 52% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around NBIX| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 2 | 10.4B USD | 96 | 64 | |
| 3 | 80.2B CNY (≈$11.2B) | 95 | 76 | |
| 3 | 21.5B USD | 95 | 60 | |
| 5 | 11.6B USD | 94 | 58 | |
| 45 | 12.7B AUD (≈$8.4B) | 65 | 38 | |
| 45 | 22.6B USD | 65 | 59 | |
| 49 | 225.2B CNY (≈$31.5B) | 64 | 63 | |
| 49 | 193.6B HKD (≈$24.8B) | 64 | 78 | |
| 49 | 16.8B USD | 64 | 75 | |
| 52 | 111.7B DKK (≈$16.8B) | 63 | 53 | |
| 52 | 28.7B USD | 63 | 52 | |
| 52 | 22.3B SGD (≈$16.9B) | 63 | 57 | |
| 52 | 10.4B USD | 63 | 70 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score